Literature DB >> 21312051

Vasopressin analogues and V1a receptor agonists in septic shock.

Marc O Maybauer, Dirk M Maybauer.   

Abstract

This article reviews the role of arginine-vasopressin and the vasopressin analogue terlipressin as potent alternative vasoconstrictors in the treatment of fluid and catecholamine-refractory septic shock. Terlipressin is the most selective, clinically available V1 receptor agonist, and may be more potent than arginine-vasopressin in restoring catecholamine refractory septic shock. Recent experimental and clinical studies on terlipressin, as well as the possible benefit of selective V1a receptor agonists, are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312051     DOI: 10.1007/s00011-011-0314-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  18 in total

Review 1.  The pathogenesis of vasodilatory shock.

Authors:  D W Landry; J A Oliver
Journal:  N Engl J Med       Date:  2001-08-23       Impact factor: 91.245

Review 2.  Terlipressin: vasopressin analog and novel drug for septic shock.

Authors:  Adam B Pesaturo; Heath R Jennings; Stacy A Voils
Journal:  Ann Pharmacother       Date:  2006-12-05       Impact factor: 3.154

Review 3.  Physiology of the vasopressin receptors.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Daniel L Traber
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2008-06

Review 4.  Review article: organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis.

Authors:  Paul Farand; Mélanie Hamel; François Lauzier; Gérard E Plante; Olivier Lesur
Journal:  Can J Anaesth       Date:  2006-09       Impact factor: 5.063

Review 5.  Aquaporins (water channels): role in vasopressin-activated water transport.

Authors:  A I Dibas; A J Mia; T Yorio
Journal:  Proc Soc Exp Biol Med       Date:  1998-12

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

7.  Terlipressin in catecholamine-resistant septic shock patients.

Authors:  Marc Leone; Jacques Albanèse; Anne Delmas; Wajdi Chaabane; Franck Garnier; Claude Martin
Journal:  Shock       Date:  2004-10       Impact factor: 3.454

8.  Continuous versus bolus infusion of terlipressin in ovine endotoxemia.

Authors:  Matthias Lange; Andrea Morelli; Christian Ertmer; Gabriele Koehler; Katrin Bröking; Christoph Hucklenbruch; Hans-Georg Bone; Hugo Van Aken; Daniel L Traber; Martin Westphal
Journal:  Shock       Date:  2007-11       Impact factor: 3.454

9.  Vasopressin versus norepinephrine infusion in patients with septic shock.

Authors:  James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

Review 10.  Vasopressin: mechanisms of action on the vasculature in health and in septic shock.

Authors:  Lucinda K Barrett; Mervyn Singer; Lucie H Clapp
Journal:  Crit Care Med       Date:  2007-01       Impact factor: 7.598

View more
  1 in total

1.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.